Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
88.50    0.00 (0.00%)
Bid:
87.00
Ask:
90.00
Spread: 3.00 (3.448%)
Market Cap: £59.37m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

R&D Day

13 Mar 2025 07:00

RNS Number : 4590A
Eco Animal Health Group PLC
13 March 2025
 

13 March 2025

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

R&D Day

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it is hosting an R&D Day today for institutional and private investors and analysts, with presentations starting at 2:00pm GMT at Andaz London, 40 Liverpool St, London EC2M 7QN.

The event will be led by David Hallas, CEO, and Chris Wilks, CFO, alongside senior leaders from across the Company and an industry expert. Attendees will have the opportunity to gain valuable insights on how the next generation of assets in ECO's R&D pipeline are driving long-term value creation and future proofing the business through innovations in preventative animal health.

For those who would like to join virtually, please register via the dedicated registration page: https://www.equitydevelopment.co.uk/news-and-events/eah-rd-investor-presentation-13march2025.

No new information will be provided on current trading at the R&D Day. For guidance on FY25 trading, the Company asks investors to review the outlook section of the interim results announced on 28 November 2024 as this remains relevant. The Company will provide a trading update for the year ending 31 March 2025 in April 2025.

 

Following the event, slides and a recording will be made available for viewing on the Investors section of the Company's website.

 

 

 

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZGMFLZLGKZM
Date   Source Headline
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022
26th Aug 20221:13 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHolding(s) in Company
22nd Aug 20227:00 amRNSRevised Notice of Results
9th Aug 20227:00 amRNSDirectorate Change
8th Aug 202211:05 amRNSSecond Price Monitoring Extn
8th Aug 202211:00 amRNSPrice Monitoring Extension
8th Aug 20227:00 amRNSNotice of Results and Trading Update
11th Jul 20227:00 amRNSNew Banking Facility
6th Jul 20227:00 amRNSPartnership with Moredun Research Institute
15th Jun 20227:35 amRNSPartnership with Imperial College
12th May 202212:05 pmRNSDirector/PDMR Dealings
29th Apr 202211:47 amRNSBlock Listing Interim Review
1st Apr 20227:00 amRNSDirector/PDMR Dealings
30th Mar 20227:00 amRNSDirector/PDMR Dealings
23rd Mar 20225:53 pmRNSDirector/PDMR Dealing
21st Mar 20227:00 amRNSDirector/PDMR Dealing
15th Mar 20227:00 amRNSPre-close Trading Update
23rd Feb 20227:00 amRNSNew Marketing Authorisations for Aivlosin in China
1st Feb 20221:53 pmRNSHolding(s) in Company
24th Jan 20227:00 amRNSInvestor Presentation
18th Jan 20227:01 amRNSHolding(s) in Company
18th Jan 20227:00 amRNSChief Executive Officer Appointment
13th Jan 20229:29 amRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update, Appointment of Joint Broker & CMD
6th Dec 20218:14 amRNSHolding(s) in Company
1st Dec 20217:00 amRNSBoard Appointment
30th Nov 202112:39 pmRNSDirector Dealings
25th Nov 20217:00 amRNSResults for the six months ended 30 September 2021
23rd Nov 20217:00 amRNSInvestor Presentation covering Interim Results
1st Oct 20218:47 amRNSTotal Voting Rights & Share Capital
27th Sep 202112:06 pmRNSDeferred Share Awards to Executive Directors
17th Sep 20217:00 amRNSResult of AGM
16th Sep 20217:00 amRNSAGM Statement
19th Aug 20217:00 amRNSPublication of Annual Report and Notice of AGM
12th Aug 20218:30 amRNSHolding(s) in Company
28th Jul 20212:40 pmRNSDirectors Dealings
26th Jul 20217:00 amRNSBoard Changes
26th Jul 20217:00 amRNSFinal Results for Year Ended 31 March 2021
28th May 20212:31 pmRNSTotal Voting Rights
12th May 20211:55 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.